Wedbush Has Positive Forecast for Prime Medicine Q2 Earnings

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Analysts at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for shares of Prime Medicine in a research note issued on Wednesday, July 16th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.40) per share for the quarter, up from their prior forecast of ($0.41). Wedbush has a "Outperform" rating and a $8.00 price objective on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine's Q3 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.81) EPS and FY2028 earnings at ($0.84) EPS.

Several other analysts also recently weighed in on PRME. JMP Securities reduced their target price on Prime Medicine from $10.00 to $6.00 and set a "market outperform" rating for the company in a report on Tuesday, May 20th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Prime Medicine in a research note on Tuesday, May 20th. HC Wainwright lowered Prime Medicine from a "buy" rating to a "neutral" rating in a research note on Tuesday, May 20th. Citigroup reaffirmed a "neutral" rating and issued a $1.50 target price (down from $10.00) on shares of Prime Medicine in a research report on Tuesday, May 27th. Finally, Chardan Capital lowered their price target on Prime Medicine from $16.00 to $12.00 and set a "buy" rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.25.

Prime Medicine Stock Performance

Prime Medicine stock opened at $4.13 on Friday. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.40. The company has a market capitalization of $555.60 million, a P/E ratio of -2.01 and a beta of 2.33. The stock has a 50-day simple moving average of $2.18 and a 200-day simple moving average of $2.22.

Insider Transactions at Prime Medicine

In other Prime Medicine news, major shareholder David R. Liu bought 21,000 shares of the business's stock in a transaction on Monday, June 23rd. The shares were purchased at an average price of $2.16 per share, with a total value of $45,360.00. Following the completion of the acquisition, the insider directly owned 20,219,945 shares of the company's stock, valued at approximately $43,675,081.20. The trade was a 0.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 63,000 shares of company stock valued at $110,250 over the last quarter. Company insiders own 22.93% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC grew its position in Prime Medicine by 24.6% during the 4th quarter. ProShare Advisors LLC now owns 22,186 shares of the company's stock worth $65,000 after purchasing an additional 4,375 shares in the last quarter. Rhumbline Advisers grew its position in Prime Medicine by 13.8% during the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company's stock worth $163,000 after purchasing an additional 9,944 shares in the last quarter. American Century Companies Inc. purchased a new position in Prime Medicine during the 4th quarter worth approximately $33,000. Virtus ETF Advisers LLC grew its position in Prime Medicine by 102.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 23,618 shares of the company's stock worth $69,000 after purchasing an additional 11,948 shares in the last quarter. Finally, Barclays PLC grew its position in Prime Medicine by 15.3% during the 4th quarter. Barclays PLC now owns 97,621 shares of the company's stock worth $285,000 after purchasing an additional 12,924 shares in the last quarter. Institutional investors and hedge funds own 70.37% of the company's stock.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.